Medicina de Emergências
Estudo randomizado | Mais dados mostram que a azitromicina não é melhor que placebo em pacientes com Covid-19.
19 Jul, 2021 | 10:06hRelacionado: RCT: Another study shows Azithromycin does not improve outcomes in patients with Covid-19. (vários artigos sobre o assunto)
Comentário no Twitter
Among outpatients with #SARSCoV2 infection, treatment with a single dose of oral #azithromycin compared with placebo did not result in a greater likelihood of being free of symptoms at day 14 https://t.co/dYDcSyGtwd #COVID19
— JAMA (@JAMA_current) July 16, 2021
Posicionamento científico | Recomendações para o uso da budesonida inalatória na COVID-19.
19 Jul, 2021 | 10:05hRecommendations for use of topical inhalant budesonide in COVID-19 – HNO
Relacionado: RCT: Inhaled budesonide shortens recovery time in non-hospitalized patients with COVID-19 E Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19
Revisão | Lesão renal aguda.
19 Jul, 2021 | 09:53hAcute kidney injury – Nature Reviews Disease Primers (gratuito por tempo limitado)
Comentário no Twitter
Get Primed on #AcuteKidneyInjury with our NEW PrimeView, FREE to download this week https://t.co/4RAOOaB8ep pic.twitter.com/d5iHCcqJwY
— Nature Reviews Disease Primers (@DiseasePrimers) July 15, 2021
Por que um grande estudo sobre ivermectina para Covid-19 foi excluído da revista onde foi publicado?
16 Jul, 2021 | 10:01hWhy Was a Major Study on Ivermectin for COVID-19 Just Retracted? – Grifter Analysis and Review
Ver também: Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns – The Guardian E Some problems in the dataset of a large study of Ivermectin for the treatment of Covid-19 – Nick Brown’s Blog E Is Ivermectin for Covid-19 Based on Fraudulent Research? – Gideon M-K; Health Nerd
Comentário no Twitter (fio – clique para saber mais)
So, one of the biggest studies to date on ivermectin for COVID-19 has issues significant enough that, if not fraud, are so serious that it invalidates the study without further explanation
I promised a thread
Here we go 1/n https://t.co/L9QOChmGtA
— Health Nerd (@GidMK) July 16, 2021
Breve revisão | O intestino na COVID-19.
16 Jul, 2021 | 09:54hThe gut in COVID-19 – Intensive Care Medicine
Comentário no Twitter
Gut & #COVID19, main findings
➡️clinical GI features
➡️pathophysiology: cytotoxic enterocyte injury, microvascular injury/thromboinfammation, non‑specifc critical illness‑related dysfunction
➡️GI dysfunction in severe #SARSCoV2 vs other critical illnesseshttps://t.co/wzzTNldInN pic.twitter.com/DnHLMsSu6v— Intens Care Med (@yourICM) July 9, 2021
Diretriz AAFP | Tratamento farmacológico das exacerbações de doença pulmonar obstrutiva crônica (DPOC).
16 Jul, 2021 | 09:49hEstudo randomizado | Banlanivimabe com etesevimabe reduz a mortalidade e a hospitalização em pacientes ambulatoriais com início de Covid-19 (até 3 dias de um teste positivo) que estão sob risco de piora clínica (p.ex., idosos, obesos, diabéticos, imunocomprometidos, portadores de doença cardiovascular).
15 Jul, 2021 | 10:41hBamlanivimab plus Etesevimab in Mild or Moderate Covid-19 – New England Journal of Medicine
Tramadol: para onde vamos a partir de agora? – “O tramadol e sua imprevisibilidade, seus inigualáveis danos potenciais e sua falta de vantagem sobre outros opioides ou anti-inflamatórios não hormonais (AINH) são agora reconhecidos.”
15 Jul, 2021 | 10:31hM-A | Utilidade da alteplase intravenosa antes do tratamento endovascular para acidente vascular cerebral.
15 Jul, 2021 | 10:23hUtility of Intravenous Alteplase Prior to Endovascular Stroke Treatment: A Systematic Review and Meta-analysis of RCTs – Neurology (link para o resumo – $ para o texto completo)
Comentário: Direct thrombectomy, bridging therapy confer similar functional outcomes in stroke – Healio (necessário cadastro gratuito)
Comentário no Twitter
Via @GreenJournal: For #patients with acute large vessel occlusion, functional outcomes were similar for those receiving direct #endovascular treatment and bridging therapy.#NeuroTwitter #neurology https://t.co/LweNGwOhVB pic.twitter.com/jqgZyV9ZOA
— Neurology Today (@NeurologyToday) June 22, 2021
Estudo randomizado | Lopinavir-ritonavir e hidroxicloroquina pioraram os desfechos em pacientes criticamente doentes com COVID-19.
14 Jul, 2021 | 11:49h
Comentário no Twitter (fio – clique para saber mais)
Results of @remap_cap #Covid_19 #Antiviral Domain released Online First @yourICM: Among critically ill patients with COVID-19, #lopinavir-ritonavir, #HydroxyChloroquine, or combination therapy worsened outcomes compared to no antiviral therapy
— remap-cap (@remap_cap) July 13, 2021